Drugs / SUM-101
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07124156 | Mar → Jul 2026 overdue | malaria | European Vaccine Initiative | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT06618885 | Aug 2025 → Jan 2026 overdue | Plasmodium falciparum malaria | European Vaccine Initiative | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SUM-101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07124156 ↗ |
| Known as | SumayaVac-1 | “Full-length MSP1/GLA-SE (SUM-101) malaria vaccine (formerly SumayaVac-1) has been developed by Sumaya Biotech, a spin-off from Heidelberg University, Germany.” NCT07124156 ↗ |
| Modality | Vaccine | “SUM-101 Malaria Vaccine” NCT06618885 ↗ |